Bacillopeptidase F (Bpr) is a fibrinolytic serine protease produced by Bacillus subtilis. Its precursor is composed of a signal peptide, an N-terminal propeptide, a catalytic domain, and a long C-terminal extension (CTE). Several active forms of Bpr have been previously reported, but little is known about the maturation of this enzyme. Here, a gene encoding a Bpr (BprL) was cloned from B. subtilis LZW and expressed in B. subtilis WB700, and three fibrinolytic mature forms with apparent molecular masses of 45, 75, and 85 kDa were identified in the culture supernatant. After treatment with urea, the 75-kDa mature form had the same molecular mass as the 85-kDa mature form, from which we infer that they adopt different conformations. Mutational analysis revealed that while the 85-kDa mature form is generated via heterocatalytic processing of a BprL proform by an unidentified protease of B. subtilis, the production of the 75-and 45-kDa mature forms involves both hetero-and autocatalytic events. From in vitro analysis of BprL and its sequential C-terminal truncation variants, it appears that partial removal of the CTE is required for the initiation of autoprocessing of the N-terminal propeptide, which is composed of a core domain (N*) and a 15-residue linker peptide, thereby yielding the 45-kDa mature form. These data suggest that the differential processing of BprL, either heterocatalytically or autocatalytically, leads to the formation of multiple mature forms with different molecular masses or conformations.
B
acillus species produce many extracellular proteases at the end of the log phase of growth (1, 2) . One of the extracellular proteases produced by B. subtilis, bacillopeptidase F (Bpr), is encoded by bpr (3), bpf (4), or hspK (5) , and its expression is dependent on the protein DegU-P (6). Bpr from B. subtilis 168 is required for the processing of the glutamic acid-specific endopeptidase Mpr, encoded by mpr (7) . However, inactivation of bpf shows that Bpr is not essential for either growth or sporulation of B. subtilis 168 (4) . Bpr is the main component of NKCP, which is a purified protein layer that is produced during B. subtilis natto fermentation and possesses fibrinolytic and antithrombotic activities (8) . Fibrinolytic activity has also been reported for Bprs from B. amyloliquefaciens (9) and B. licheniformis (10, 11) .
Bprs belong to the superfamily of subtilisin-like serine proteases (subtilases) (12) . They are synthesized as large precursors (ϳ1,430 amino acid residues) consisting of a signal peptide, an N-terminal propeptide, a catalytic domain that shares approximately 30% sequence identity to subtilisins, and a long C-terminal extension (CTE) of approximately 900 amino acid residues (3) (4) (5) 9) . The signal peptide of a subtilase precursor mediates the enzyme's secretion across the cytoplasmic membrane and is cleaved by a signal peptidase to generate the proform. Subsequently, the N-terminal propeptide, which usually functions as an intramolecular chaperone to facilitate the correct folding of the mature domain and as a potential inhibitor of the mature enzyme, is autoprocessed from the proform to release the active mature enzyme (13) . In the case of Bpr, several active forms with apparent molecular masses ranging from 33 kDa to 90 kDa have been identified (3-5, 8, 9, 14-16) . The multiple active forms of Bpr may result from the processing of the N-terminal propeptide and the truncation of the CTE (4, 5) , but the molecular basis for Bpr maturation is unclear. In addition, the CTE of Bpr is not essential for enzyme activity or secretion (4) , and its function is unknown.
Recently, we have isolated a fibrinolytic B. subtilis strain, LZW, from soil. In this study, a gene encoding a bacillopeptidase F (bprL) was cloned from this strain and expressed in B. subtilis WB700 and Escherichia coli to investigate the in vivo and in vitro processing mechanisms of this enzyme. We conclude that the maturation of BprL involves both hetero-and autocatalytic processes and that either the N-terminal propeptide or the CTE is processed in a stepwise manner to yield several active mature forms with different molecular masses and conformations. In addition, we found that the CTE plays an important role in maintaining BprL in an inactive state. Deletion analysis revealed that partial removal of the CTE is required for the initiation of autoprocessing of the enzyme to generate the 45-kDa mature form.
MATERIALS AND METHODS
Strains and growth conditions. B. subtilis LZW was isolated from soil at Wuhan University, China, and has been deposited in the China Center for Type Culture Collection (CCTCC) under accession number CCTCC AB2015270. B. subtilis WB700 (trpC2 nprE aprE epr bpr ⌬mpr::ble ⌬nprB:: bsr ⌬vpr::ery), a strain deficient in seven extracellular proteases (17) , was used as the host for expression. E. coli DH5␣ and E. coli BL21(DE3) were used as the hosts for cloning and expression, respectively. Bacteria were grown in 50 ml of Luria-Bertani (LB) medium in a 250-ml flask at 37°C with shaking (180 rpm). Where necessary, the medium was supplemented with 100 g/ml ampicillin or 30 g/ml kanamycin. Fibrin plate assay. Fibrin plates were prepared as described by Kim et al. (18) with modifications. Briefly, 2.5 ml of bovine fibrinogen (Sigma, St. Louis, MO, USA) solution (2.2 mg/ml in 10 mM sodium phosphate buffer [pH 7.8]; sterilized by filtration) was mixed with 10 ml of sterilized LB medium containing 1.5% agar (all percentages are wt/vol unless otherwise indicated) that was warmed in a 45°C water bath. After the addition of 0.5 ml of bovine thrombin (Sigma) solution (20 NIH U/ml in 10 mM sodium phosphate buffer [pH 7.8]; sterilized by filtration), the mixture was poured into a petri dish and kept at room temperature for 1 h to form fibrin clots. Thereafter, bacterial strains were inoculated on the fibrin plates and incubated at 37°C for 24 h. Colonies with surrounding clear zones were classified as fibrinolytic strains.
DNA manipulation, plasmid construction, and mutagenesis. The genomic DNA of B. subtilis LZW and plasmids were prepared by standard protocols (19) and used as templates for PCR. The oligonucleotide sequences of the primers used in this study are listed in Table 1 . The gene encoding the BprL precursor was amplified from B. subtilis LZW genomic DNA with LA-Taq DNA polymerase (TaKaRa, Otsu, Japan) by PCR using primers P-F and P-R (Table 1) , which were designed based on the sequence of the bpr gene of B. subtilis 168 (3, 4) . The amplified DNA fragment was then ligated into the pMD18-T vector (TaKaRa) to construct the plasmid pMD18-bprL (Table 2) for sequencing.
The E. coli-B. subtilis shuttle plasmid pBE2 (20) was used as the vector for the production of BprL in B. subtilis WB700. The DNA fragment containing the coding region of the BprL precursor ( Fig. 1 ) and its own promoter (see Fig. S1 in the supplemental material) was amplified from the plasmid pMD18-bprL by PCR with Pfu DNA polymerase (Fermentas, Burlington, Canada) using primers B-F and B-R1 (Table 1) and inserted into the PstI-BamHI restriction site of pBE2 to construct the expression plasmid pBE2-bprL for BprL ( Table 2 ). The expression plasmid pBE2-bprL⌬C912 for the CTE deletion variant BprL⌬C912 (Table 2 ) was also constructed as described above by cloning the PCR product obtained with primers B-F and B-R2 (Table 1) .
To produce recombinant proteins in E. coli BL21(DE3) and to facilitate the DNA manipulation, plasmid pETx was constructed based on the plasmids pET26b and pET28a (Novagen). Briefly, the 85-bp DNA fragment, which contained a NheI restriction site between the NdeI and XhoI sites of pET28a, was amplified by PCR using primers U-F and U-R (Table  1) and then ligated into the NdeI-XhoI restriction site of pET26b, thereby yielding the plasmid pETx ( Table 2 ). The genes encoding the proforms of BprL and its sequential C-terminal truncation variants (BprL⌬C511, BprL⌬C678, and BprL⌬C912), as well as the CTE fragment (BprLC912) (Fig. 1) were amplified from pMD18-bprL by PCR using primer pairs listed in Table 2 . The amplified genes were then inserted into the NheIXhoI restriction site of plasmid pETx to generate expression plasmids for target proteins ( Table 2) .
The QuikChange site-directed mutagenesis method (21) was employed to construct expression plasmids for active-site variants of BprL (BprLS258A), BprL⌬C678 (BprL⌬C678-S258A and BprL⌬C678-S258C), and BprL⌬C912 (BprL⌬C912-S258A and BprL⌬C912-S258C) using primer pairs and templates listed in Table 2 . The sequences of all recombinant plasmids were confirmed by DNA sequencing.
Expression, purification, and in vitro processing. B. subtilis WB700 cells harboring expression plasmids for BprL and its variants were grown at 37°C with constant shaking (180 rpm) in LB medium containing 30 g/ml of kanamycin. When the culture was in the late log phase (24 h), it was centrifuged at 10,000 ϫ g for 10 min at 4°C. The supernatant was collected and used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), immunoblot analyses, and a fibrin overlay assay.
E. coli BL21(DE3) cells harboring expression plasmids for BprL and its 
a Underlining indicates the restriction enzyme sites used in this study. The mutated nucleotides are in bold. Italic indicates the His 6 tag-encoding DNA sequences. Restriction site
SA-F/SA-R pETx-bprL pETx-bprL⌬C678-S258A SA-F/SA-R pETx-bprL⌬C678 pETx-bprL⌬C678-S258C SC-F/SC-R pETx-bprL⌬C678 pETx-bprL⌬C912-S258A SA-F/SA-R pETx-bprL⌬C912 pETx-bprL⌬C912-S258C SC-F/SC-R pETx-bprL⌬C912 variants were grown at 37°C until the optical density at 600 nm reached approximately 0.6. Production of recombinant protein was induced by the addition of 0.4 mM isopropyl-␤-D-thiogalactopyranoside, and the cultivation was continued at 37°C for 4 h. The cells were harvested, suspended in 50 mM sodium phosphate buffer (pH 7.5) containing 0.5 mM NaCl (referred to here as buffer A), and disrupted by sonication on ice. After centrifugation at 13,000 ϫ g for 10 min, the insoluble fraction was collected and solubilized in buffer A containing 8 M urea (urea buffer). The solubilized fraction was centrifuged at 13,000 ϫ g for 10 min, after which the supernatant was collected and subjected to affinity chromatography on an Ni 2ϩ -charged chelating Sepharose Fast Flow resin (GE Healthcare) column equilibrated with urea buffer. The column was washed with 40 mM imidazole in urea buffer. Bound proteins were eluted with 100 mM imidazole in urea buffer. The elution fraction was then dialyzed overnight (4°C) against buffer A to remove the imidazole and urea and allow the denatured protein to refold. Thereafter, the sample was incubated at 30°C to allow for enzyme processing. During the incubation, aliquots of the sample were subjected to SDS-PAGE analysis and azocaseinolytic activity assay.
Protein concentrations were determined using the Bradford method (22) . The amounts of target proteins in the samples containing degradation products or contaminating proteins were further assessed by band intensity measurement following SDS-PAGE, using bovine serum albumin as a standard. The enzyme solution was concentrated with a Micron TM-3 centrifugal filter (Millipore, Bedford, MA, USA) as needed.
Enzyme activity assay. Azocaseinolytic activity of the enzyme was determined at 37°C for 1 h in 400 l of reaction mixture, which consisted of 200 l of enzyme sample and 0.25% azocasein in buffer A. The reaction was terminated by the addition of 400 l of 40% trichloroacetic acid (TCA) to the reaction mixture. After incubation at room temperature for 15 min, the mixture was centrifuged at 13,400 ϫ g for 10 min, and the absorbance of the supernatant was measured at 335 nm (A 335 ) in a 1-cm cell. One unit of activity was defined as the amount of enzyme required to increase the A 335 by 0.01 unit/min under the conditions described above.
SDS-PAGE and fibrin overlay assay. SDS-PAGE was carried out with the glycine-Tris system (23) . To prevent self-degradation of the protease during sample preparation (boiling) or electrophoresis, the samples for conventional SDS-PAGE analysis were precipitated with 20% TCA. After incubation at room temperature for 15 min, the precipitated proteins were recovered by centrifugation at 13,400 ϫ g for 10 min and resuspended in ice-cold acetone, and the proteins were recovered by centrifugation at 13,400 ϫ g for 10 min. The proteins were then air dried, boiled in the loading buffer unless otherwise indicated, and subjected to SDS-PAGE. After electrophoresis, the gel was stained with Coomassie brilliant blue G-250. Where necessary, targetstained protein bands were excised from the gel, and the gel slices were incubated at 80°C for 20 min in urea buffer to extract proteins. The extracted proteins were precipitated with 20% TCA and then subjected to SDS-PAGE after boiling in the loading buffer containing 8 M urea to investigate the influence of urea treatment on electrophoretic mobility of the protein in SDS-PAGE.
For activity staining of fibrinolytic enzyme, samples without TCA treatment were mixed with 5ϫ loading buffer and subjected to SDS-PAGE without boiling. Meanwhile, a fibrin-polyacrylamide gel was prepared as described previously (24) . The SDS-polyacrylamide gel and the fibrin-polyacrylamide gel were subjected to a fibrin overlay assay using the procedure described by Blumentals et al. (25) , except that the fibrinolytic reaction was carried out at 37°C for 15 h in buffer A. To determine the molecular masses of the fibrinolytic enzymes, protein bands on a replicate SDS-polyacrylamide gel were visualized by staining with 0.25 M KCl as described previously (26) , and the target bands corresponding to the fibrinolytic bands, as determined by fibrin overlay assay, were excised from the gel. The proteins were extracted from the gel slices with urea buffer containing 10 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma), precipitated with 20% TCA, and subjected to immunoblot analysis after boiling in loading buffer containing 8 M urea.
Immunoblot analysis. BprL⌬C912 comprises the N-terminal propeptide and catalytic domain, and BprLC912 comprises the CTE fragment of BprL. They were produced in E. coli BL21(DE3) and served as antigens for the generation of antibodies in rabbits. Antisera against BprL⌬C912 (anti-NM) and BprLC912 (anti-C) were prepared and used for immunoblot analysis as described previously (27) . In some cases, the His tag monoclonal antibody (Novagen) was used for immunoblot analysis as described previously (27) .
N-terminal sequencing. After separation by SDS-PAGE, the proteins were electroblotted onto a polyvinylidene difluoride membrane and stained with Coomassie brilliant blue R-250. The target protein bands were excised and subjected to N-terminal amino acid sequence analysis using a PPSQ-33A protein sequencer (Shimadzu, Kyoto, Japan).
Nucleotide sequence accession number. The sequence of the region coding for BprL, including the open reading frame (ORF) and its flanking sequences, has been deposited in GenBank under accession number KT259045. 
RESULTS
Cloning and sequencing of the gene encoding BprL from Bacillus subtilis LZW. Using the primers P-F and P-R (Table 1) , a 4,793-bp DNA fragment was amplified from the genome of B. subtilis LZW. DNA sequencing of this fragment revealed that the ORF encoding the BprL with 1,433 amino acid residues (Fig. 1) is preceded by a DegU-dependent promoter (6) and is followed by a putative transcription termination site (see Fig. S1 in the supplemental material). A comparison with other known Bprs suggests that the BprL precursor is composed of a signal peptide of 30 residues, an N-terminal propeptide of 164 residues, a catalytic domain of 327 residues, and a long CTE of 912 residues (Fig. 1) . The BprL precursor shares 98%, 97%, and 70% amino acid sequence identities with Bpr precursors from B. subtilis natto (5), B. subtilis 168 (3), and B. amyloliquefaciens CH86-1 (9), respectively. The nonconserved residues are located mainly within the CTE (see Fig. S2 in the supplemental material). While the catalytic domains of BprL and B. subtilis 168 Bpr have an identical amino acid sequence, it differs from that of B. subtilis natto Bpr by only three amino acid substitutions (see Fig. S2 in the supplemental material).
Production and processing of BprL and its variants in B. subtilis. The culture supernatant of the control strain, B. subtilis WB700(pBE2), was compared with that of B. subtilis WB700(pBE2-bprL), producing BprL, by SDS-PAGE. At least four additional protein bands with apparent molecular masses of 85, 75, 45, and 33 kDa were detected in the latter ( Fig. 2A) . To investigate whether these additional protein bands were derived from BprL, the culture supernatant of B. subtilis WB700(pBE2-bprL) was subjected to immunoblot analysis using anti-NM or anti-C antibodies. While the 45-and 33-kDa proteins were detected only with anti-NM and anti-C antibodies, respectively, the 85-and 75-kDa proteins were detected by both antibodies (Fig.  2A) . This indicates that all four proteins are processed products of BprL; among them, the 45-kDa product lacks the CTE and the 33-kDa product is a fragment of the CTE. The SDS-PAGE profile of the proteins did not change markedly after incubation of the culture supernatant of B. subtilis WB700(pBE2-bprL) at 40°C for 9 h (data not shown), suggesting that the four proteins are stable processed products of BprL. Interestingly, pretreatment of the sample with urea-containing loading buffer slowed migration of the 75-kDa product on SDS-PAGE, so that its migration rate was consistent with that of the 85-kDa product (Fig. 2B, lane ϩU) . Moreover, after extraction from the gel with urea solution, the 75-kDa product also displayed an apparent molecular mass of 85 kDa (Fig. 2B, lane ϩU=) . We interpret these results to mean that the 75-kDa product adopts a conformation different from that of the 85-kDa product. Also, it is relatively resistant to acid (TCA) treatment but sensitive to urea treatment.
The first four residues of the 45-kDa product were identified as ATDG by N-terminal sequencing, indicating that the N-terminal propeptide has been processed at the peptide bond Lys Ϫ1 -Ala 1 ( Fig. 1) . N-terminal sequencing of the 85-kDa product revealed two polypeptides, with the first four residues identified as those of the 45-kDa product (ATDG) and the residues (SSSP) upstream of the peptide bond Lys Ϫ1 -Ala 1 , respectively, implying that the generation of the 85-kDa product involves multiple processing of the N-terminal propeptide (Fig. 1) .
Besides the 85-, 75-, 45-, and 33-kDa products, many minor protein fragments were detected by anti-NM and/or anti-C antibodies in the culture supernatant of B. subtilis WB700(pBE2-bprL) but were absent in that of B. subtilis WB700(pBE2) (Fig. 2A) , indicating that they were processing intermediates or degradation products of BprL. Many more of these minor fragments were detected by anti-C antibodies than by anti-NM antibodies, which suggested that the CTE of BprL is more sensitive to proteolysis than its catalytic domain. The culture supernatant of strain LZW had an immunoblot pattern of the processed products from BprL that was similar to that for B. subtilis WB700(pBE2-bprL) ( Fig.  2A) , suggesting that BprL undergoes multiple proteolytic processing in vivo.
It is known that replacing the catalytic residue Ser with Ala abolishes the activity of subtilases but does not affect enzyme folding (28, 29) . To investigate whether the multiple proteolytic processing of BprL occurs auto-or heterocatalytically, the culture supernatant of B. subtilis WB700(pBE2-bprLS258A) producing the active-site variant BprLS258A was subjected to SDS-PAGE and immunoblot analyses. Three protein bands with apparent molecular masses of approximately 150, 110, and 85 kDa were detected ( Fig. 2A) . The 150-and 110-kDa products may represent the secreted proform with a calculated molecular mass of 151.5 kDa and a processed intermediate of BprLS258A. Since the 150-and 110-kDa products were not detected in the culture supernatant of B. subtilis WB700(pBE2-bprL) ( Fig. 2A) , it is apparent that the active site of BprL mediates the conversion of the 150-and 110-kDa proteins to other products. Nevertheless, the 85-kDa product and some of the minor protein fragments were found in culture supernatants of both B. subtilis WB700(pBE2-bprLS258A) and B. subtilis WB700(pBE2-bprL) ( Fig. 2A) , indicating that their production is independent of the active site of BprL but relies on proteolytic activity elaborated by the host. Moreover, N-terminal sequencing of the 85-kDa product of BprLS258A revealed two polypeptides with the first four amino acid residues identified as ATDG and SSSP, which are identical to those of the 85-kDa product of BprL. These results demonstrate that the in vivo processing of BprL involves both auto-and heterocatalytic events.
When the BprL⌬C912 precursor was produced in B. subtilis WB700, the 45-kDa product was detected in the culture supernatant by SDS-PAGE and immunoblotting using anti-NM antibodies ( Fig. 2A) , confirming that the CTE is not required for the secretion of BprL. In addition, the 45-kDa product could be detected by anti-His tag antibody and purified by Ni 2ϩ affinity chromatography (Fig. 2C) , suggesting that no further C-terminal processing occurred during the conversion of BprL⌬C912 to the 45-kDa product. Therefore, the 45-kDa product contains only the 327-residue catalytic domain with a C-terminal His tag and represents the smallest mature form of BprL, similar to the active component of NKCP from B. subtilis natto (8) . The predicted molecular mass of the smallest mature form of BprL is 34.4 kDa, and it is predicted to have a pI of 3.8. The predicted molecular mass is lower than its apparent molecular mass of 45 kDa as determined by SDS-PAGE analysis; this is a common phenomenon with acidic proteins (30) .
Detection of fibrinolytic activity of BprL. The fibrinolytic activity of BprL was evidenced by the finding that a clear zone was formed around the colony of B. subtilis WB700(pBE2-bprL) grown on the fibrin plate (Fig. 3A) . In contrast, the clear zone did not appear around the colonies of B. subtilis WB700, B. subtilis WB700(pBE2), or B. subtilis WB700(pBE2-bprLS258A) (Fig. 3A) . In addition, the formation of a clear zone around the colony of B. subtilis WB700(pBE2-bprL⌬C912) suggests that the CTE is not required for fibrinolytic activity of BprL (Fig. 3A) . A fibrin overlay assay revealed fibrinolytic bands in the culture supernatants (without TCA treatment) of B. subtilis WB700(pBE2-bprL), B. subtilis WB700(pBE2-bprL⌬C912), and B. subtilis WB700(pBE2) (Fig. 3B ). There were four bands associated with B. subtilis WB700 (pBE2-bprL), two with B. subtilis WB700(pBE2-bprL⌬C912), and one with B. subtilis WB700(pBE2) (Fig. 3B) . The fibrinolytic band c was present in the culture supernatants of all three strains (Fig.  3B ), indicating that it is an unknown fibrinolytic enzyme of the host. The fibrinolytic protein bands a, b, and d were extracted from the gel, precipitated with TCA, and then subjected to immunoblot analysis using anti-NM antibodies after pretreatment with urea-containing loading buffer (Fig. 3C) . We found that the fibrinolytic band d represented the 45-kDa product of BprL (Fig.  3C, lane d) . The fibrinolytic bands a and b, which were present in the culture supernatant of B. subtilis WB700(pBE2-bprL) but absent in that of B. subtilis WB700(pBE2-bprL⌬C912) (Fig. 3B) , showed an apparent molecular mass of 85 kDa after treatment with urea (Fig. 3C, lanes a and b) . Therefore, the fibrinolytic bands a and b corresponded to the 85-kDa and 75-kDa products of BprL, respectively. These results demonstrate that the 85-, 75-, and 45-kDa products are three mature forms of BprL with fibrinolytic activity.
In vitro processing of BprL and its variants. Our next objective was to assess whether BprL can mature properly in vitro. The role of the long CTE in enzyme maturation was also investigated. We constructed recombinant proforms of BprL and its sequential C-terminal truncation variants (BprL⌬C511, BprL⌬C678, and BprL⌬C912) and active-site variant (BprLS258A), as well as the CTE fragment (BprLC912) (Fig. 1) . The recombinant proteins with a C-terminal His tag were produced in E. coli, purified under denaturing conditions, dialyzed at 4°C overnight, and incubated at 30°C to allow enzyme refolding and processing. BprL and BprL⌬C511 were degraded after dialysis and incubation, as shown by SDS-PAGE analysis (Fig. 4A) , and had very weak proteolytic activity (data not shown). Under the same conditions, BprLS258A (band e) was not degraded but was converted into a product (band f) with slightly lower apparent molecular mass than band e (Fig.  4A) . No proteolytic activity was detected in the sample of BprLS258A (data not shown), and band f could be converted into band e after treatment with 8 M urea (Fig. 4A) . Therefore, we suggest that bands e and f represent the two forms of BprLS258A with different conformations. Apparently, BprL and BprL⌬C511 do not fold properly and adopt an unstable active conformation that undergoes autodegradation. Moreover, immunoblot analysis showed that the main processed products (85, 75, and 45 kDa) of BprL detected in the culture supernatant of B. subtilis WB700 (pBE2-bprL) were absent in the in vitro processing sample of BprL (Fig. 4D) , demonstrating a major difference between in vivo and in vitro processing of BprL. In contrast, BprL⌬C912 and BprL⌬C678 were converted into the 45-kDa mature form, detected by anti-NM antibodies (Fig. 4B, C, and D) , indicating that the two proteins were properly folded and autoprocessed. These results suggest that partial removal of the CTE (more than 511 residues from the C terminus) is required for the initiation of autoprocess-
FIG 3 Fibrinolytic activities of BprL and its variant. (A) B. subtilis WB700 (Bs),
B. subtilis WB700 harboring pBE2 or the expression vector pBE2-bpr, pBE2-bprLS258A, or pBE2-bprL⌬C91, and B. subtilis LZW were grown on fibrin plates at 37°C for 24 h. (B) The culture supernatant, without TCA treatment or boiling, of B. subtilis WB700 harboring pBE2 or the expression vector pBE2-bprL or pBE2-bprL⌬C912 was subjected to SDS-PAGE (lanes s) followed by a fibrin overlay assay (lanes f). The closed arrowheads indicate the BprL-and BprL⌬C912-derived products with fibrinolytic activity. (C) The proteins bands that correspond to the fibrinolytic bands a, b, and d were extracted from a replicate SDS-polyacrylamide gel, precipitated with 20% TCA, boiled in loading buffer containing 8 M urea, and subjected to anti-NM immunoblot analysis.
FIG 4 In vitro processing of BprL and its variants. (A to C) The denatured
samples (lanes U) of BprL and its variants (0.5 M) were dialyzed overnight at 4°C against buffer A to allow the denatured proteins to refold (lanes R) and then incubated at 30°C. At the time intervals indicated, samples were withdrawn and subjected to conventional SDS-PAGE analysis and azocaseinolytic activity assay. The refolded sample of BprLS258A (lanes 2d) was supplemented with 8 M urea and then incubated at 30°C for 24 h (lanes 2d=), followed by SDS-PAGE analysis. The two forms of BprLS258A (e and f) are indicated (A). Relative activity was calculated with the highest measured activity defined as 100% (B and C). (D) The culture supernatant (24 h) of B. subtilis WB700 harboring an expression vector for BprL (lanes 1) and the in vitro processing samples (48 h) of BprL (lanes 2), BprL⌬C678 (lanes 3), and BprL⌬C912 (lanes 4) were subjected to conventional SDS-PAGE and anti-NM or anti-C immunoblot analysis. The closed arrowheads indicate the major processed products of BprL. The positions on the gels of the proforms (P and P=), the intermediates (Ia, Ia=, and Ib=), the 45-kDa mature form (M), the processed core domain of the N-terminal propeptide (N*), and the degradation product of the CTE (C5=) are indicated.
ing of BprL into the active 45-kDa mature enzyme and demonstrate the importance of the CTE in maintaining BprL in an inactive state.
BprL⌬C912 was cleaved into a 47-kDa intermediate (Ia) and N* after dialysis, and Ia was further processed into the 45-kDa mature enzyme (M) as incubation time increased (Fig. 4B) . The first four residues of the 47-kDa Ia and the 45-kDa M were determined to be SSSP and ATDG (Fig. 1) , respectively, demonstrating that the 15 N-terminal residues of Ia were truncated to yield M. Therefore, the N-terminal propeptide of BprL is composed of a core domain (N*) and a 15-residue linker peptide (Fig. 1) . The autoprocessing of linker peptide-containing N-terminal propeptides of subtilisins involves initial cis processing of N* and subsequent trans processing of the linker peptide (28) . Likewise, the removal of the N-terminal propeptide of BprL proceeded in a stepwise manner by cis processing of N* at Lys Ϫ16 -Ser Ϫ15 and trans processing of the linker peptide at Lys Ϫ1 -Ala 1 (Fig. 1) . In addition, the degradation of N* was accompanied by the release of proteolytic activity (Fig. 4B) , suggesting that the N-terminal propeptide of BprL is an inhibitor of the enzyme. Similar to BprL⌬C912, BprL⌬C678 was initially converted into an intermediate (Ia=) by cleavage of N*, followed by processing of Ia= into M via another intermediate (Ib=) (Fig. 4C ). BprL⌬C678 has 234 more residues in its CTE than BprL⌬C912, and we suggest that the conversion of Ia= into M involved trans processing of both the linker peptide and the partial CTE. The appearance of the intermediate Ib= and several smaller fragments that were less than 30 kDa as well as the accumulation of degradation product C5= during the conversion (Fig. 4C ) support this suggestion.
Unlike BprL⌬C912 and BprL⌬C678, which could be autoprocessed into active 45-kDa mature enzyme, the active-site variants BprL⌬C912-S258A and BprL⌬C678-S258A remained unprocessed after refolding and incubation alone (Fig. 5A and B, ϪM) , providing strong evidence that the active site of BprL mediates autoprocessing of the N-terminal propeptide. In contrast, both BprL⌬C912-S258A and BprL⌬C678-S258A were converted into a 45-kDa mature form when incubated with supplemental 45-kDa mature enzyme (Fig. 5A and B, ϩM) , indicating that the N-terminal propeptide of the proform could be intermolecularly cleaved by the active mature enzyme. The size of the major cleaved N-terminal propeptide of BprL⌬C912-S258A or BprL⌬C678-S258A (Fig. 5A and B, ϩM, lane R) was similar to that of the cis-processed N* of BprL⌬C912 or BprL⌬C678 (Fig. 4B and C) , suggesting that the initial cleavage of the N-terminal propeptide occurs mainly within the linker peptide of the proform. In the case of BprL⌬C678-S258A, which contains a partial CTE, both the N-terminal propeptide and the partial CTE were processed by supplemental 45-kDa mature enzyme; the appearance of the intermediate Ib= suggests that the partial CTE is trans processed in a stepwise manner (Fig. 5B ). These results demonstrate that the catalytic domain in the variant of the BprL proform with a full or partial deletion of the CTE is properly folded and adopts a proteolysis-resistant conformation, allowing active protease to trans process the variant into the 45-kDa mature form.
In subtilases, the replacement of the catalytic residue Ser with Cys greatly reduces enzyme activity but does not eliminate its autoprocessing activity, so that the maturation process is blocked after the initial cis processing of the N-terminal propeptide (28, 29) . Similarly, the variant BprL⌬C912-S258C or BprL⌬C678-S258C itself was converted into the intermediate Ia or Ia= by cis processing of N* but could not be further processed into the 45-kDa mature form (Fig. 5C and D, ϪM) . We found that the cisprocessed N* of BprL⌬C912, BprL⌬C912-S258C, BprL⌬C678, or BprL⌬C678-S258C coeluted with Ia or Ia= from an Ni 2ϩ -charged column (data not shown), implying that the cleaved N* was still bound to Ia or Ia= to form an autoprocessed complex (N*-Ia or N*-Ia=), as has been reported for other subtilisins (28, 29) . In the presence of the active 45-kDa mature enzyme, either N*-Ia or N*-Ia= was trans processed into the 45-kDa mature form (Fig. 5C and D, ϩM), indicating that the cleaved N* and the partial CTE in the autoprocessed complex are more susceptible to proteolysis than the catalytic domain.
DISCUSSION
Based on these results, we propose the following mechanism for BprL maturation in B. subtilis. Maturation proceeds via both hetero-and autocatalytic steps that yield several fibrinolytic mature forms with apparent molecular masses of 45, 75, and 85 kDa. Partial removal of the CTE of the proform may trigger autoprocessing of the N-terminal propeptide, which is composed of a core domain (N*) and a 15-residue linker peptide. Complete removal of the N-terminal propeptide and the CTE leads to the generation of the 45-kDa mature form.
The 85-kDa mature form is generated via heterocatalytic processing of the proform by an unidentified protease of B. subtilis. Data from N-terminal sequencing of the 85-kDa mature form lead us to suggest that the N-terminal propeptide is processed at two cleavage sites within the linker peptide. Similarly, proteolytic cleavage of the N-terminal propeptide within the linker peptide of Bpr from B. subtilis 168 or B. subtilis natto leads to generation of an 80-kDa or a 90-kDa mature form (4, 5) . The serine protease inhibitor PMSF does not prevent the production of the 80-kDa mature form of Bpr in B. subtilis 168 (4), a finding that may indicate that another protease(s) participates in the processing of the enzyme. Heterocatalytic removal of the N-terminal propeptide via proteolytic cleavage at the linker peptide has been described for other subtilases, notably the WF146 protease from thermophilic Bacillus sp. strain WF146 (28) and the protease CDF from Thermoactinomyces sp. strain CDF (27) . In this context, the linker peptide of subtilases comprises a proteolytically sensitive region, allowing trans processing of the N-terminal propeptide by other proteases. Moreover, the BprL with its N-terminal propeptide deleted has a predicted molecular mass of 133.2 kDa, which is higher than that of the 85-kDa mature form. This indicates that in addition to the N-terminal propeptide, part of the CTE has been processed during the conversion of the BprL proform to the 85-kDa mature form, although the exact C-terminal cleavage site remains to be determined.
The production of the 75-and 45-kDa mature forms involves both hetero-and autocatalytic events. BprL alone is not autoprocessed into the 75-and 45-kDa mature forms in vitro, and it may be that an unknown protease of B. subtilis participates in the in vivo conversion of BprL into the two mature forms. The in vitro analyses of BprL and its C-terminal truncation variants reveal that partial removal of the CTE is required for the generation of the 45-kDa mature form. Because the variant BprL⌬C678, but not BprL⌬C511, can be autoprocessed into the 45-kDa mature form, the in vivo production of the 45-kDa mature form in B. subtilis is most likely triggered by heterocatalytic processing of the CTE; the cleavage site would then be located between Leu561 and Glu728 (Fig. 1) . After partial removal of the CTE, the 45-kDa mature form is generated autocatalytically by cis processing of the core domain of the N-terminal propeptide (N*), and subsequent trans processing of both the linker peptide and the remaining part of the CTE. In comparison with the 45-kDa mature form, the 75-kDa mature form contains part of the CTE. However, it is unlikely that the 75-kDa mature form is an intermediate during the conversion of BprL to the 45-kDa mature form, since both forms are stable maturation products of BprL. An alternative possibility is that the CTE of BprL contains several cleavage sites for an unidentified protease(s) of B. subtilis and that differential proteolytic processing of the CTE leads to multiple intermediates with different conformations. In some intermediates, after autoprocessing of the N-terminal propeptide, the remaining part of the CTE is susceptible to proteolysis and would be trans processed completely to generate the 45-kDa mature form. In other intermediates, the remaining part of the CTE is resistant to proteolysis such that their C termini either would not be processed further or would only be truncated partially after autoprocessing of the N-terminal propeptide, thereby yielding the 75-kDa mature form. Notably, the 75-kDa mature form, which displays an apparent molecular mass of 85 kDa after urea denaturation, differs from the 85-kDa mature form in its resistance to acid treatment. This may be due to its adoption of a conformation different from that of the 85-kDa mature form (heterocatalytic maturation product). In this context, differential processing of BprL, either heterocatalytically or autocatalytically, leads to the formation of mature forms with different molecular masses or conformations.
Multiple mature forms have been described for other CTEcontaining subtilases, such as Vpr (31, 32) and Epr (33, 34) from B. subtilis and pyrolysin from Pyrococcus furiosus (35, 36) . Maturation of these enzymes also involves differential proteolytic processing of the CTE. The mature form of Vpr isolated from B. subtilis has a molecular mass of 28.5 kDa (31) , but in vitro analysis shows that this enzyme can be autoprocessed into multiple mature forms with fibrinolytic activity and ranging from 40 to 68 kDa, although the 28.5-kDa form has not been detected (32) . It may be that another protease(s) of B. subtilis contributes to the in vivo production of the 28.5-kDa form of Vpr, similar to the case of the 45-kDa mature form of BprL. Nevertheless, BprL differs from Vpr in that BprL alone is not processed into stable mature forms; rather, it requires another protease(s) to partially cleave the CTE and thus to mature properly.
There are at least 27 proteases in the membrane, cell wall, and medium of B. subtilis that can process or degrade secretory proteins (1, 2). Two major extracellular proteases (AprE and NprE) account for more than 95% of the total extracellular protease activity of B. subtilis (37) , while five minor extracellular or cell wallassociated proteases (Epr, Vpr, Bpr, Mpr, and WprA) are responsible for most of the remaining activity (31, 33, 38, 39) . The principal function of extracellular proteases, including Bpr, is thought to be supplying nutrients for bacterial growth by degrading extracellular proteins, although additional physiological functions have also been described for some of these proteases. For instance, Epr (40) and Vpr (41, 42) are involved in swarming motility of B. subtilis. AprE, WprA, and Vpr are reported to play a role in processing and activation of the antibiotic peptide subtilin, and a function for Bpr and Epr in this process cannot be ruled out (43) . Notably, single-cell analyses revealed that only part of the vegetative subpopulation of B. subtilis cells highly and transiently expresses genes encoding Bpr and AprE (44) . As these proteases and their degradation products freely diffuse within the liquid growth medium, all cells within the entire population are expected to benefit from their activities, suggesting that B. subtilis employs cooperative or even altruistic behavior (44) . Seven of the known proteases, specifically AprE, Bpr, Epr, Mpr, NprB, NprE, and Vpr, are not required for BprL processing, as their genes are inactivated in B. subtilis WB700 (17) . However, we do not exclude the possibility that some or all of these proteases are involved in Bpr processing in wild-type B. subtilis and may accelerate Bpr maturation. Interestingly, Bpr is required for the processing of Mpr (7), which is a glutamic acid-specific endopeptidase (45) . Here, we found that Bpr itself requires an unidentified protease for maturation, and perhaps there exists a protease activation cascade that regulates extracellular proteolytic activity in B. subtilis. The long CTE of BprL is not essential for enzyme activity and secretion but plays an important role in maintaining BprL in an inactive state and thus may contribute to the regulation of the protease activation cascade in B. subtilis. We noticed an unknown fibrinolytic enzyme in the culture supernatant of B. subtilis WB700. The identification of this enzyme and its possible relation to BprL maturation awaits future experimental endeavor. 
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